Rubicon Research: The financial results for the period ended September 30, 2026
Rubicon Research (RUBICON) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹28,787 crore.
What happened
Rubicon Research (RUBICON) filed a disclosure with the exchanges on 5 November 2026 at 04:06 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
Rubicon Research is a small-cap company in the Healthcare sector, with a market value of about ₹28,787 crore.
The stock last traded at ₹1,740.6, against a 52-week range of ₹609.3–₹1,899 (8.3% below the high).
Before this filing the shares had moved +5.3% over the month and +13.3% over three months. Average daily turnover over the last 20 sessions was about ₹28.86 crore.
Promoters held 59.76% at the end of Q1 FY27, down 0.10% points from the previous quarter. Foreign institutions owned 7.52% and domestic institutions 9.43%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 412 | 53.9 | 3.49 |
| Q3 FY26 | 476 | 72.8 | 4.46 |
| Q4 FY26 | 514 | 76.8 | 4.66 |
| Q1 FY27 | 534 | 84.8 | 5.13 |
What history shows
This is not the company's first results disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 29.5% on average the next trading day and was up 17.5% on average after five days (2 filings with price data).
Across 300 similar disclosures by other Healthcare companies, shares moved +1.4% on average the next day and +1.9% over five days; 57% of them rose the next day.
Market-wide, 10,790 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 29 May 2026 | Audited Financial Results For The Quarter And Year Ended 31 March… | +29.5% | +17.5% |
| 29 May 2026 | Board Meeting Outcome for Audited Financial Results For The Quarter… | +29.5% | +17.5% |
Market reaction so far
Since the filing, the stock has risen 1.3%, from ₹1,718 before the disclosure to ₹1,740.6 (live price).
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 5 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- General Atlantic sells 8.45% stake in Rubicon Research
- Rubicon Research Limited (RUBICON.NS) stock price, news, quote and history
- Rubicon Research Limited Schedules Q2 FY27 Call for November 5
- Rubicon Research Receives Five USFDA Observations at Ambernath Facility
- Rubicon Research - Vedanta Power among 6 stocks showing bullish RSI upswing
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.